AEGiS-Glasgow [PL9.3] Similar profile of adverse events during treatment for tuberculosis in patients with and without HIV co-infection

Seventh International Congress on Drug Therapy in HIV Infection

Glasgow, UK - 14-17 November 2004

[PL9.3] Similar profile of adverse events during treatment for tuberculosis in patients with and without HIV co-infection

Int Cong Drug Therapy HIV 2004 Nov 14-18;7:Abstract No. PL9.3

Ronan Breen¹, Robert Miller², Jayne Ballinger¹, Leonie Swaden¹, Margaret Johnson¹, Marc Lipman¹
¹Royal Free Hospital; ²RF & UC Medical School, London, UK

To describe the adverse events profile when both HAART and anti-tuberculosis medication are used together.

Case-note review of 115 patients with active HIV/TB coinfection, compared to 114 unselected HIV negative TB patients treated over the same time period at our institution.

HIV+ TB+ patients had a median age of 34 and 52% were female (similar to HIV- controls). Rifamycin-based regimens were used in 98% of both populations. Median duration of TB treatment was 6 months (range 3-36). 84/115 (73%) HIV/TB patients received HAART during their TB treatment. This was PI-based n=26, NNRTI-based n=45, triple NRTI-based n=13. HAART was started a median of 2 months (range 0-7) after TB treatment. TB treatment was interrupted in 13 of 115 (11%) HIV+TB+ against 10 of 114 (9%) HIV-TB+. Hepatic toxicity was responsible in 8 of 13 and 8 of 10 cases respectively. Causes of grade 3/4 toxicity in the HIV+TB+ patients were peripheral neuropathy [PN] n=16 (14%); rash n=10 (9%); transaminitis n=8 (7%); persistent vomiting n=10 (9%). This compared to PN n=4 (4%); rash n=3 (3%); transaminitis n=8 (7%); persistent vomiting n=4 (4%) in the HIV- group. HAART was stopped in 6 of 84 (7%) (poor adherence = 2, failing regimen = 3, IRIS=1); altered in 15 (common reasons: pill burden n=4, PN n=3, Abacavir hypersensitivity n=3, anaemia due to AZT n=2). 110 of 115 HIV+TB+ patients completed TB treatment, compared to 99 of 114 HIV-TB+ patients.

Anti-TB medication has a similar adverse event profile in HIV+ and HIV- individuals. HAART is associated with an increase in such events but these do not lead to more treatment interruptions.

SESSION 9: HIV-RELATED INFECTIONS, CO-INFECTIONS AND MALIGNANCIES

2004-11-14
PL9.3

Copyright © 2004 - Thomson ACUMED® All rights reserved. Thomson ACUMED® is an intelligent and innovative medical marketing and communications agency – a new division of The Gardiner-Caldwell Group Ltd, part of The Thomson Corporation, located in Tytherington, UK.

Reproduction of this abstract (other than one copy for personal reference) must be cleared through the authors.